<DOC>
	<DOCNO>NCT00002190</DOCNO>
	<brief_summary>To explore antiviral efficacy , tolerability safety saquinavir plus zidovudine plus lamivudine .</brief_summary>
	<brief_title>A Phase II Open-Label Exploratory Study Saquinavir + Zidovudine + Lamivudine HIV Infected Patients</brief_title>
	<detailed_description>A total 30 patient receive triple drug regimen saquinavir plus zidovudine plus lamivudine completion analysis least 4 week therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV antibody positive . CD4 count &gt; = 150 &lt; = 500 cells/mm3 . Exclusion Criteria Prior Medication : Excluded : Prior antiretroviral therapy . Prior protease inhibitor therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>